Therapeutic effect and safety of apatinib plus carilizumab combined with low-dose radiotherapy as first-line treatment for advanced hepatocellular carcinoma
Objective:To investigate the therapeutic effect and safety of apatinib plus carilizumab combined with low-dose radiotherapy(LDRT)as first-line treatment for advanced hepatocellular carcinoma(HCC).Methods:A retrospective analysis was conducted on the data of advanced HCC patients admitted to our hospital from July 2020 to December 2021.They were divided into Apatinib+Carilizumab group(A+C group,41 cases)and Apatinib+Carilizumab combined with LDRT group(A+C+LDRT group,45 cases).Patients in the A+C group received oral apatinib 250 mg/d and intravenous carilizumab 200 mg/3 weeks,while patients in the A+C+LDRT group received LDRT(20-30 Gy/10 F/2 W)on the basis of the A+C group.The recent therapeutic effect,overall survival rate,progression free survival rate,objective response rate,disease control rate,and incidence of adverse events were compared between the two groups.Results:The median overall survival and median progression free survival in the A+C+LDRT group were longer than those in the A+C group(P＜0.05).Male,≤60 years old,at BCLC stage C,maximum tumor diameter＞10 cm,number of tumors＞3,accompanied by portal vein tumor thrombus,accompanied by HBV infection,no extrahepatic metastasis,AFP＞200 ng/ml,residual normal liver volume≥1000 ml were factors more likely to benefit from apatinib plus carilizumab combined with LDRT(P＜0.05).Most of the adverse events in the two groups were classified as grade 1-2.Except for nausea and vomiting,there was no statistically significant difference in the incidence of adverse events between the two groups(P＞0.05).Conclusion:In the first-line treatment of advanced HCC patients,compared with apatinib plus carilizumab,apatinib plus carilizumab combined with LDRT can significantly improve overall survival and progression free survival,and has tolerable adverse events.
万方数据
维普
